131 related articles for article (PubMed ID: 2540096)
1. Effect of the platelet-activating factor antagonist BN 52021 on human natural killer cell cytotoxicity.
Mandi Y; Farkas G; Koltai M; Beladi I; Braquet P
Int Arch Allergy Appl Immunol; 1989; 88(1-2):222-4. PubMed ID: 2540096
[TBL] [Abstract][Full Text] [Related]
2. The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity.
Mandi Y; Farkas G; Koltai M; Beladi I; Mencia-Huerta JM; Braquet P
Immunology; 1989 Jul; 67(3):370-4. PubMed ID: 2759659
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide-derived PAF antagonist, BN 52021.
Kurihara K; Wardlaw AJ; Moqbel R; Kay AB
J Allergy Clin Immunol; 1989 Jan; 83(1):83-90. PubMed ID: 2536413
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
5. Effects of the platelet-activating factor antagonist BN 52021 on anti-islet cytotoxicity of mononuclear cells and serum from type 1 (insulin-dependent) diabetic patients.
Köhler E; Varnai G; Knospe S; Förster W; Michaelis D; Wanka H
Int Arch Allergy Appl Immunol; 1991; 95(4):352-5. PubMed ID: 1959976
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.
Földes-Filep E; Braquet P; Filep J
Biochem Biophys Res Commun; 1987 Nov; 148(3):1412-7. PubMed ID: 2825685
[TBL] [Abstract][Full Text] [Related]
7. [The effect of platelet-activating factor and its antagonist--BN 52021--on immune reactions in vivo in mice and in vitro].
Poveshchenko AF; Kozlov VA
Zh Mikrobiol Epidemiol Immunobiol; 1999; (4):53-6. PubMed ID: 10852052
[TBL] [Abstract][Full Text] [Related]
8. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
9. Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model.
Cruzado JM; Torras J; Riera M; Lloberas N; Herrero I; Condom E; Martorell J; Alsina J; Grinyó JM
Clin Exp Immunol; 1998 Jul; 113(1):136-44. PubMed ID: 9697996
[TBL] [Abstract][Full Text] [Related]
10. Effects of platelet-activating factor on electrophysiology of isolated retinas and their inhibition by BN 52021, a specific PAF-acether receptor antagonist.
Doly M; Bonhomme B; Braquet P; Chabrier PE; Meyniel G
Immunopharmacology; 1987 Jun; 13(3):189-94. PubMed ID: 3038784
[TBL] [Abstract][Full Text] [Related]
11. Role of platelet-activating factor in long-term potentiation of the rat medial vestibular nuclei.
Grassi S; Francescangeli E; Goracci G; Pettorossi VE
J Neurophysiol; 1998 Jun; 79(6):3266-71. PubMed ID: 9636125
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.
Lachachi H; Plantavid M; Simon MF; Chap H; Braquet P; Douste-Blazy L
Biochem Biophys Res Commun; 1985 Oct; 132(2):460-6. PubMed ID: 2998370
[TBL] [Abstract][Full Text] [Related]
13. Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-alfa-mediated cytotoxicity on murine L929 tumor cells.
Hunyadi J; Kenderessy AS; Duda E; Braquet P; Dobozy A
Mol Immunol; 1993 Apr; 30(6):517-9. PubMed ID: 7683748
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.
Piper PJ; Stewart AG
Br J Pharmacol; 1987 Apr; 90(4):771-83. PubMed ID: 3034369
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
16. The accumulation of platelet activating factor in the injured cornea may be interrelated with the synthesis of lipoxygenase products.
Bazan HE; Reddy ST; Woodland JM; Bazan NG
Biochem Biophys Res Commun; 1987 Dec; 149(3):915-20. PubMed ID: 2827658
[TBL] [Abstract][Full Text] [Related]
17. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
[TBL] [Abstract][Full Text] [Related]
18. [Platelet-activating factor (PAF) antagonists].
Terasawa M
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
[No Abstract] [Full Text] [Related]
19. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.
Filep JG; Sirois MG; Rousseau A; Fournier A; Sirois P
Br J Pharmacol; 1991 Dec; 104(4):797-804. PubMed ID: 1667286
[TBL] [Abstract][Full Text] [Related]
20. Proof of the involvement of platelet activating factor (paf-acether) in pulmonary complex immune systems using a specific paf-acether receptor antagonist: BN 52021.
Touvay C; Vilain B; Taylor JE; Etienne A; Braquet P
Prog Lipid Res; 1986; 25(1-4):277-88. PubMed ID: 2827186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
